To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …

Methods BEL-7402 cells were treated with sorafenib or paclitaxel alone or in three different
schedules: sorafenib was give prior to, after, or simultaneously with paclitaxel. The half …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

HepG2 cells were treated with different concentrations of sorafenib or adriamycin alone or
their combination to investigate the inhibitory effect of sorafenib in combination with …

HepG2 cells were exposed to sorafenib, irinotecan, and oxaliplatin and then subjected to
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …

Objective To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP)
on the proliferation of hepatocellular carcinoma cells and explore the molecular …

Background The outcomes for patients with advanced hepatocellular carcinoma (HCC)
receiving sorafenib are far from satisfactory because of treatment resistance to sorafenib …

Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma
(HCC). The mechanism underlying this effect is not completely understood. In this work we …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …